/KPRX

KPRX Stock - Kiora Pharmaceuticals, Inc.

Q: What is the analyst price target for KPRX?

Analyst price target information is not currently available for KPRX.

Q: What is KPRX's market cap?

Market capitalization information is not currently available for KPRX.

Healthcare|Biotechnology|NASDAQ

$2.16+2.86%

+$0.06 (+2.86%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.38

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KPRX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.75

52W High$4.18

52W Low$1.76

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$16.00M	N/A	N/A	N/A	$12,059
Gross Profit	$16.00M	N/A	N/A	N/A	$-3,260,592
Gross Margin	100.0%	N/A	N/A	N/A	-27038.7%
Operating Income	$4.51M	$-12,586,896	$-12,309,523	$-14,235,768	$-6,868,868
Net Income	$3.59M	$-12,513,896	$-13,583,610	$-13,770,685	$-6,861,770
Net Margin	22.5%	N/A	N/A	N/A	-56901.7%
EPS	$0.93	$-24.25	$-18.55	$-68.00	$-70.50

Company Overview

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Visit Website

Earnings History & Surprises

KPRX

Beat Rate

61%

Last 18 quarters

Avg Surprise

-107.5%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$0.01

Q4 2025

EPS Surprise History

Q1 24

-11.9%

$-0.47vs$-0.42

Q2 24

-38.7%

$3.42vs$5.58

Q3 24

+44.2%

$-0.53vs$-0.95

Q4 24

+10.0%

$-0.81vs$-0.90

Q1 25

-62.5%

$-1.04vs$-0.64

Q2 25

+32.5%

$-0.52vs$-0.77

Q3 25

+6.9%

$-0.54vs$-0.58

Q4 25

+101.4%

$0.01vs$-0.72

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 24, 2026	$-0.70	—	—	—
Q4 2025	Nov 7, 2025	$-0.72	$0.01	+101.4%	✓ BEAT
Q3 2025	Aug 8, 2025	$-0.58	$-0.54	+6.9%	✓ BEAT
Q2 2025	May 9, 2025	$-0.77	$-0.52	+32.5%	✓ BEAT
Q1 2025	Mar 25, 2025	$-0.64	$-1.04	-62.5%	✗ MISS
Q4 2024	Nov 8, 2024	$-0.90	$-0.81	+10.0%	✓ BEAT
Q3 2024	Aug 9, 2024	$-0.95	$-0.53	+44.2%	✓ BEAT
Q2 2024	May 10, 2024	$5.58	$3.42	-38.7%	✗ MISS
Q1 2024	Mar 28, 2024	$-0.42	$-0.47	-11.9%	✗ MISS
Q4 2023	Nov 9, 2023	$-2.70	$-8.01	-196.7%	✗ MISS
Q3 2023	Aug 8, 2023	$-4.59	$-7.11	-54.9%	✗ MISS
Q2 2023	May 9, 2023	$-1.68	$-1.00	+40.5%	✓ BEAT
Q1 2023	Mar 23, 2023	$-2.46	$-1.76	+28.5%	✓ BEAT
Q4 2022	Nov 9, 2022	$-3.83	$-39.15	-922.2%	✗ MISS
Q3 2022	Aug 12, 2022	$-72.01	$-64.81	+10.0%	✓ BEAT
Q3 2022	Jul 8, 2022	$-9.20	$-97.21	-956.6%	✗ MISS
Q2 2022	Apr 15, 2022	—	$-280.83	—	—
Q4 2021	Nov 15, 2021	$-122.41	$-104.41	+14.7%	✓ BEAT
Q3 2021	Aug 12, 2021	$-16.67	$-14.00	+16.0%	✓ BEAT
Q2 2021	May 12, 2021	$-15.40	$-14.80	+3.9%	✓ BEAT

Frequently Asked Questions about KPRX

What is KPRX's current stock price?

Kiora Pharmaceuticals, Inc. (KPRX) is currently trading at $2.16 per share. The stock has moved +2.86% today.

What is the analyst price target for KPRX?

No analyst price targets are currently available for this stock.

What sector is Kiora Pharmaceuticals, Inc. in?

Kiora Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KPRX's market cap?

Kiora Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.

Does KPRX pay dividends?

No, Kiora Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.